ACORDA THERAPEUTICS, INC.
ACORUnited States
36 filed reports · 510 financial concepts
Latest figures
Group totals as stated in the company’s own filed reports, each with a link to its report. The change is against the same period a year earlier.
Latest fiscal year
Filed reports
36 reports · Jun 2015 to Mar 2024Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 27 | 4,118 | Jun 2015 to Mar 2024 |
| Annual · 10-KSEC EDGAR | 8 | 3,885 | Dec 2015 to Dec 2023 |
| Annual · 10-K/ASEC EDGAR | 1 | 445 | Dec 2017 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2024 Q1 | 10-Q | 2024-03-31 | 2024-05-14 | 315 | Open |
| FY2023 | 10-K | 2023-12-31 | 2024-04-01 | 668 | Open |
| FY2023 Q3 | 10-Q | 2023-09-30 | 2023-11-14 | 225 | Open |
| FY2023 Q2 | 10-Q | 2023-06-30 | 2023-08-09 | 198 | Open |
| FY2023 Q1 | 10-Q | 2023-03-31 | 2023-05-11 | 139 | Open |
| FY2022 | 10-K | 2022-12-31 | 2023-03-15 | 437 | Open |
| FY2022 Q3 | 10-Q | 2022-09-30 | 2022-11-14 | 177 | Open |
| FY2022 Q2 | 10-Q | 2022-06-30 | 2022-08-09 | 148 | Open |
| FY2022 Q1 | 10-Q | 2022-03-31 | 2022-05-13 | 148 | Open |
| FY2021 | 10-K | 2021-12-31 | 2022-03-18 | 483 | Open |
| FY2021 Q3 | 10-Q | 2021-09-30 | 2021-11-12 | 180 | Open |
| FY2021 Q2 | 10-Q | 2021-06-30 | 2021-08-12 | 149 | Open |
Financial data
510 concepts · 8,448 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial501 concepts · 8,221 facts · Dec 2013 to Mar 2024
- Allocated share based compensation expense52 · Dec 2013 to Mar 2024
- Cash and cash equivalents at carrying value52 · Dec 2013 to Mar 2024
- Income tax expense benefit52 · Dec 2013 to Mar 2024
- Interest expense (US GAAP)52 · Dec 2013 to Mar 2024
- Investment income interest52 · Dec 2013 to Mar 2024
- Net income loss52 · Dec 2013 to Mar 2024
- Nonoperating income expense52 · Dec 2013 to Mar 2024
- Operating income loss52 · Dec 2013 to Mar 2024
- Research and development expense52 · Dec 2013 to Mar 2024
- Revenue52 · Dec 2013 to Mar 2024
- Selling general and administrative expense52 · Dec 2013 to Mar 2024
- Depreciation depletion and amortization50 · Dec 2013 to Mar 2024
- Income taxes paid50 · Dec 2013 to Mar 2024
- Increase decrease in accounts payable and accrued liabilities50 · Dec 2013 to Mar 2024
- Increase decrease in accounts receivable50 · Dec 2013 to Mar 2024
- Increase decrease in finished goods and work in process inventories50 · Dec 2013 to Mar 2024
- Increase decrease in prepaid deferred expense and other assets50 · Dec 2013 to Mar 2024
- Other comprehensive income loss net of tax portion attributable to parent50 · Dec 2013 to Mar 2024
- Share based compensation50 · Dec 2013 to Mar 2024
- Deferred income tax expense benefit49 · Dec 2013 to Dec 2023
- Common stock shares authorized48 · Dec 2014 to Mar 2024
- Fair value measurement with unobservable inputs reconciliations recurring basis liability value48 · Dec 2014 to Mar 2024
- Accounts payable current47 · Dec 2014 to Mar 2024
- Accounts receivable net current47 · Dec 2014 to Mar 2024
Product5 concepts · 212 facts · Dec 2016 to Mar 2024
- Revenue200 · Dec 2016 to Mar 2024
- Amortization of intangible assets5 · Dec 2018 to Dec 2022
- Contract with customer liability revenue recognized5 · Dec 2016 to Dec 2020
- Asset impairment charges1 · Dec 2017
- Impairment of intangible assets finitelived1 · Mar 2017
Segment1 concept · 8 facts · Dec 2019 to Sep 2021
- Effective income tax rate reconciliation at federal statutory income tax rate8 · Dec 2019 to Sep 2021
Geography3 concepts · 7 facts · Dec 2020 to Mar 2024
- Base Rent Subject To Annual Escalation Percentage3 · Dec 2022 to Mar 2024
- Termination Fee3 · Dec 2022 to Dec 2023
- Proceeds from divestiture of businesses1 · Dec 2020
Segments
227 factsFigures broken down by business line, region, product or another axis the company reports on.
Product or servicesrt:ProductOrServiceAxis10 members · 206 facts
- Net Product Revenues37 · Dec 2016 to Mar 2024
- Royalty Revenues37 · Dec 2016 to Mar 2024
- Ampyra33 · Dec 2017 to Mar 2024
- License Revenue29 · Dec 2016 to Mar 2024
- Inbrija26 · Mar 2019 to Mar 2024
- Other17 · Dec 2017 to Sep 2021
- Inbrija U.S.11 · Mar 2021 to Dec 2023
- Inbrija ex-U.S.10 · Mar 2022 to Mar 2024
- Milestone Revenues5 · Sep 2020 to Dec 2020
- SYN-1201 · Dec 2017
Statement business segments1 member · 8 facts
- CARES Act8 · Dec 2019 to Sep 2021
Statement geographical3 members · 7 facts
- Ardsley, New York3 · Dec 2022 to Dec 2023
- Pearl River, New York3 · Dec 2022 to Mar 2024
- Chelsea, Massachusetts1 · Dec 2020
Product or serviceus-gaap:ProductOrServiceAxis4 members · 6 facts
- Net Product Revenues2 · Mar 2017 to Mar 2018
- Royalty Revenues2 · Mar 2017 to Mar 2018
- Ampyra1 · Mar 2017
- License Revenue1 · Mar 2017
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Ask about this company in your AI model
Connect FactIQ to Claude, ChatGPT or another AI model (how to install), then paste this prompt.
Use FactIQ to get the revenue, net income and operating income of ACORDA THERAPEUTICS, INC. (ACOR) from its filed reports, for the last five fiscal years and the latest quarter or half year. Link each figure to its filing, and chart the trend.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Nov 19, 2026) and refreshed every few hours.